Press Releases
- Active Biotech AB - Year-end report January - December 2019 February 6, 2020 08:30 (CET)Regulatory
- Active Biotech announces new direction February 5, 2020 08:30 (CET)Regulatory
- Active Biotech's election committee appointed November 19, 2019 16:00 (CET)
- Active Biotech Interim report January – September 2019 November 14, 2019 08:30 (CET)Regulatory
- New preclinical data on naptumomab estafenatox will be presented at the Society for Immunotherapy of Cancer’s 34th Annual Meeting November 5, 2019 11:00 (CET)Regulatory
- Active Biotech and NeoTX today announce first patient dosed in the Phase 1b trial of naptumomab estafenatox in combination with durvalumab in solid tumors October 28, 2019 08:30 (CET)Regulatory
- Active Biotech: New data on laquinimod from the Phase 2 LEGATO-HD study in Huntington’s disease will be presented at the International congress of Parkinson’s disease and movement disorders September 23, 2019 08:30 (CEST)Regulatory
- Active Biotech AB: Interim report January – June 2019 August 8, 2019 08:30 (CEST)Regulatory
- Annual General Meeting of Active Biotech AB May 23, 2019 20:00 (CEST)Regulatory
- The Phase 2 LEGATO-HD study of laquinimod in Huntington's disease will be presented at the scientific conference "American Academy of Neurology - AAN" in Philadelphia, PA, on May 6 2019 May 3, 2019 13:00 (CEST)Regulatory